Dr Hans Erickson | Director of Protein Chemistry
Genentech

Dr Hans Erickson, Director of Protein Chemistry, Genentech

After receiving my Ph.D. in Biochemistry from UCSD and a NIH postdoctoral fellowship at the University of Utah, I joined ImmunoGen, a biotechnology company in the Boston area focused on developing Antibody-Drug Conjugates (ADCs).  During my 11 years at ImmunoGen I had the opportunity to contribute to the advancement of several ADCs into the clinic including KadcylaTM which was approved for the treatment of patients with metastatic breast cancer in 2013.  In 2014 I joined Genentech where I currently lead a group focused on the production and characterization of novel proteins and conjugates for therapeutic applications such as engineered antibodies, antibody fragments, chemically-linked multimers, and ADCs.

Appearances:



Day 1 Antibody Congress @ 16:01

Understanding the factors that drive stability of protein conjugates

Plenary
  •     Antibodies with cysteine mutations for conjugation are widely used for the preparation of homogeneous ADCs with defined molar ratios between the payload to the antibody. 
  •     The factors that drive stability are not well understood. 
  •     How we have optimized our cysteine engineering (THIOMAB™) technology to build better ADCs at Genentech will be discussed.

back to speakers